Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01760655 · ClinicalTrials.gov registry record · Phase 2
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT01760655 is a Phase 2 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. The registered enrollment target is 62 participants.
The verdict
NCT01760655, a Phase 2 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
This phase II trial studies reduced-intensity conditioning before donor stem cell transplant in treating patients with high-risk hematologic malignancies. Giving low-doses of chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Giving an infusion of the donor's T cells (donor lymphocyte infusion) before the transplant may help increase this effect.
Interventions
- DRUG Cyclophosphamide
- DRUG Busulfan
- DRUG Fludarabine phosphate
- RADIATION Total-Body Irradiation
- BIOLOGICAL Therapeutic Allogeneic Lymphocytes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2012-12-24 |
| Est. Completion | 2022-12-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01760655
The ClinicalTrials.gov registry entry for NCT01760655 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT01760655 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01760655 about?
NCT01760655 is a clinical study titled "Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies". This phase II trial studies reduced-intensity conditioning before donor stem cell transplant in treating patients with high-risk hematologic malignancies. Giving low-doses of chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells. It may als...
What is the current status of trial NCT01760655?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2012-12-24. Estimated completion is 2022-12-05.
What interventions are being tested in trial NCT01760655?
The interventions under investigation include: Cyclophosphamide (DRUG), Busulfan (DRUG), Fludarabine phosphate (DRUG), Total-Body Irradiation (RADIATION), Therapeutic Allogeneic Lymphocytes (BIOLOGICAL).
Who is sponsoring clinical trial NCT01760655?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.